These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28607329)

  • 1. Effect of long-term physical activity on PCSK9, high- and low-density lipoprotein cholesterol, and lipoprotein(a) levels: a prospective observational trial.
    Sponder M; Campean IA; Dalos D; Emich M; Fritzer-Szekeres M; Litschauer B; Bergler-Klein J; Graf S; Strametz-Juranek J
    Pol Arch Intern Med; 2017 Aug; 127(7-8):506-511. PubMed ID: 28607329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
    Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
    J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
    J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).
    Zhang X; Stiekema LCA; Stroes ESG; Groen AK
    Lipids Health Dis; 2020 May; 19(1):91. PubMed ID: 32393252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
    Langsted A; Nordestgaard BG; Benn M; Tybjærg-Hansen A; Kamstrup PR
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3281-7. PubMed ID: 27218270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
    Du Q; Yu XJ; Li HJ; Guan SQ; Zhang ZY; Mei YF
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):655-659. PubMed ID: 28870033
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
    Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
    Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacing Saturated Fats with Unsaturated Fats from Walnuts or Vegetable Oils Lowers Atherogenic Lipoprotein Classes Without Increasing Lipoprotein(a).
    Tindall AM; Kris-Etherton PM; Petersen KS
    J Nutr; 2020 Apr; 150(4):818-825. PubMed ID: 31909809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
    Filippatos TD; Kei A; Rizos CV; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
    Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.